HPV vaccination to prevent cervical cancer and other HPV-associated disease: From basic science to effective interventions

Journal of Clinical Investigation

Volumn 126, Issue 1, 2016, Pages 5-11

  Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE; VIRUS ANTIBODY;

ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOGENICITY; NONHUMAN; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; UTERINE CERVIX CANCER; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; WART VIRUS; ANIMAL; BLOOD; BOVINE PAPILLOMAVIRUS TYPE 1; CLINICAL TRIAL (TOPIC); DISEASE MODEL; IMMUNOLOGY; MALE; UTERINE CERVICAL NEOPLASMS; VIRION;

ANIMALS; ANTIBODIES, VIRAL; BOVINE PAPILLOMAVIRUS 1; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VIRION;

EID: 84956598415     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI85446     Document Type: Article

References (51)

1. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384(2):260-265.
2. Huh WK, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136(2):178-182.
3. Androphy AJ, Lowy DR, Schiller JT. Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature. 1987;325(6099):70-73.
4. Androphy EH, Schiller JT, Lowy DR. Indentification of the protein encoded by the E6 transforming gene of bovine papillomavirus. Science. 1985;230(4724):442-445.
5. Schiller JT, Vass WC, Vousden KH, Lowy DR. E5 open reading frame of bovine papillomavirus type 1 encodes a transforming gene. J Virol. 1986;57(1):1-6.
6. Kreimer AR, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444-1451.
7. Safaeian M, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila). 2013;6(11):1242-1250.
8. Howley PM, Schiller JT, Lowy DR. Papillomaviruses. In: Knipe DM, Howley PM, eds. Fields Virology. 6th ed. Philadelphia, Pennsylvania, USA: Wolters Kluwer/Lippincott Williams & Willkins; 2013:1662-1703.
9. Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235-3242.
10. International Human Papillomavirus Reference Center. HPV Center Web site. http://www.hpvcenter. se/. Accessed November 17, 2015.
11. Bosch FX, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31(suppl 7):H1-H31.
12. Saraiya M, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086.
13. Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev. 2013;22(4):553-560.
14. Dvoretzky I, Shober R, Chattopadhyay SK, Lowy DR. Focus assay in mouse cells for bovine papillomavirus. Virology. 1980;103(2):369-375.
15. Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol. 1994;75(pt 8):2075-2079.
16. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A. 1992;89(24):12180-12184.
17. Kirnbauer R, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993;67(12):6929-6936.
18. Roden RB, et al. In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol. 1996;70(9):5875-5883.
19. Roberts JN, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007;13(7):857-861.
20. Schiller JT, Lowy DR. Papillomavirus-like particles and HPV vaccine development. Semin Cancer Biol. 1996;7(6):373-382.
21. Roden RB, Hubbert NL, Kirnbauer R, Christensen ND, Lowy DR, Schiller JT. Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol. 1996;70(5):3298-3301.
22. Pastrana DV, Vass WC, Lowy DR, Schiller JT. An HPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology. 2001;279(1):361-369.
23. Harro CD, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93(4):284-292.
24. Koutsky LA, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347(21):1645-1651.
25. Harper DM, et al. Efficacy of a bivalent L1 viruslike particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004;364(9447):1757-1765.
26. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(suppl 5):F123-F138.
27. Einstein MH, et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother. 2014;10(12):3435-3445.
28. Lowy DR, Herrero R, Hildesheim A. Correction to Lancet Oncol 2015; 16:e227.
29. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol. 2015;16(7):e313.
30. Lowy DR, Herrero R, Hildesheim A, Participants in the INCIwoPEfPHPVVT. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol. 2015;16(5):e226-e233.
31. Chow EP, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214-219.
32. Crowe E, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ. 2014;348:g1458.
33. Drolet M, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: A systematic review and metaanalysis. Lancet Infect Dis. 2015;15(5):565-580.
34. Markowitz LE, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208(3):385-393.
35. Gee J, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279-8284.
36. Stokley S, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014 - United States. MMWR Morb Mortal Wkly Rep. 2014;63(29):620-624.
37. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.
38. Naud PS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147-2162.
39. Engels EA, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer. 2008;123(1):187-194.
40. Day PM, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe. 2010;8(3):260-270.
41. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol. 2012;10(10):681-692.
42. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc Natl Acad Sci U S A. 2009;106(48):20458-20463.
43. Dobson SR, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA. 2013;309(17):1793-1802.
44. Romanowski B, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modelling predictions from a randomized study [published online ahead of print July 15, 2015]. Hum Vaccin Immunother. doi:10.1080/21645515.2015.1065363.
45. Kreimer AR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol. 2015;16(7):775-786.
46. Stanley MA, Sudenga SL, Giuliano AR. Alternative dosage schedules with HPV viruslike particle vaccines. Expert Rev Vaccines. 2014;13(8):1027-1038.
47. Schiller JT, Lowy DR. Raising expectations for subunit vaccine. J Infect Dis. 2015;211(9):1373-1375.
48. Joura EA, et al. Ngan Y, Petersen LK, Lazcano-Ponce E, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723.
49. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest. 2001;108(3):415-423.
50. Crossey E, et al. A cholesterol-lowering VLP vaccine that targets PCSK9. Vaccine. 2015;33(43):5747-5755.
51. Schiller JT, Muller M. Next generation prophylactic human papillomavirus vaccines. Lancet Oncol. 2015;16(5):e217-e225.